<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108419</url>
  </required_header>
  <id_info>
    <org_study_id>NU327</org_study_id>
    <nct_id>NCT01108419</nct_id>
  </id_info>
  <brief_title>Evaluation of Dose-effect of a New Fermented Food in Healthy Adults</brief_title>
  <official_title>Evaluation of the Safety and Tolerance of a New Fermented Food in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and tolerance of a new fermented food versus a&#xD;
      control product in healthy adults during the 4-week consumption period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on adverse events.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Number of Adverse events, number of AE related to product, number of emergent AE, number of mild/moderate and severe AE, number of serious AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Systolic/diastolic blood pressure (mmHg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Heart rate (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Weight (kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Body mass index (kg/m²).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Temperature (°C).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Hemoglobin (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Hematocrit (L/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Red blood cell, white blood cell, platelets (count/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on glucose and lipids metabolism.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>blood glucose (mmol/L), lipids [total cholesterol, HDL, LDL, triglycerides] (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on liver function.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Blood alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase (IU/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on kidney function.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Blood creatinin (μmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on thyroid function.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Blood thyroid stimulating hormone (mU/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on blood marker of inflammation.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Blood C-reactive protein (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on fecal marker of inflammation.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Fecal calprotectin (μg/g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on bowel habits.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Stool frequency and consistency (Bristol Stool Scale from 1 [hard stools] to 7 [watery stools]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on digestive symptoms.</measure>
    <time_frame>During the 4-week period of product consumption.</time_frame>
    <description>Frequency of abdominal pain/discomfort, abdominal bloating, flatulence, borborygmi/rumbling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on adverse events.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Number of Adverse events, number of AE related to product, number of emergent AE, number of mild/moderate and severe AE, number of serious AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Systolic/diastolic blood pressure (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Heart rate (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Weight (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Body mass index (kg/m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Temperature (°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Hemoglobin (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Hematocrit (L/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Red blood cell, white blood cell, platelets (count/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on glucose and lipids metabolism.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>blood glucose (mmol/L), lipids [total cholesterol, HDL, LDL, triglycerides] (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on liver function.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase (IU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on kidney function.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood creatinin (μmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on thyroid function.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood thyroid stimulating hormone (mU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on blood marker of inflammation.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood C-reactive protein (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on fecal marker of inflammation.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Fecal calprotectin (μg/g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on bowel habits.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Stool frequency and consistency (Bristol Stool Scale from 1 [hard stools] to 7 [watery stools]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on digestive symptoms.</measure>
    <time_frame>During the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Frequency of abdominal pain/discomfort, abdominal bloating, flatulence, borborygmi/rumbling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on adverse events.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Number of Adverse events, number of AE related to product, number of emergent AE, number of mild/moderate and severe AE, number of serious AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Systolic/diastolic blood pressure (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Heart rate (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Weight (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Body mass index (kg/m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product vital signs.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Temperature (°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Hemoglobin (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Hematocrit (L/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on hematology.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Red blood cell, white blood cell, platelets (count/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on glucose and lipids metabolism.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>blood glucose (mmol/L), lipids [total cholesterol, HDL, LDL, triglycerides] (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on liver function.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase (IU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on kidney function.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood creatinin (μmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on thyroid function.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood thyroid stimulating hormone (mU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on blood marker of inflammation.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Blood C-reactive protein (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on fecal marker of inflammation.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Fecal calprotectin (μg/g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on bowel habits.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Stool frequency and consistency (Bristol Stool Scale from 1 [hard stools] to 7 [watery stools]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on digestive symptoms.</measure>
    <time_frame>During the 4-week period of product consumption, the 4-week follow-up period and the 8-week entire study period.</time_frame>
    <description>Frequency of abdominal pain/discomfort, abdominal bloating, flatulence, borborygmi/rumbling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on test product strains detection and quantification in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Concentration of test product bacterial strains in feces by quantitative PCR (bacterial cells/g of feces).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on microbiota analysis in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Gut microbiota analysis by sequencing approaches (16S rRNA and shotgun sequencing): Alpha (index) and beta-diversity (distance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1 bottle/day of test versus control product on microbiota analysis in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Gut microbiota analysis by sequencing approaches (16S rRNA and shotgun sequencing): relative abundance of bacterial genera (%) and metabolic pathways (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on test product strains detection and quantification in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Concentration of test product bacterial strains in feces by quantitative PCR (bacterial cells/g of feces).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on microbiota analysis in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Gut microbiota analysis by sequencing approaches (16S rRNA and shotgun sequencing): Alpha (index) and beta-diversity (distance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 3 bottles/day of test versus control product on microbiota analysis in feces.</measure>
    <time_frame>During the 4-week period of product consumption and after 4-week follow-up period.</time_frame>
    <description>Gut microbiota analysis by sequencing approaches (16S rRNA and shotgun sequencing): relative abundance of bacterial genera (%) and metabolic pathways (%).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1 = Test Product normal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fermented dairy product containing probiotics - normal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 = Test Product high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fermented dairy product containing probiotics - high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 = Control Product normal dose</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Non-fermented dairy product - normal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 = Control Product high dose</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Non-fermented dairy product - high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fermented dairy product</intervention_name>
    <arm_group_label>1 = Test Product normal dose</arm_group_label>
    <arm_group_label>2 = Test Product high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>milk-based non-fermented dairy product</intervention_name>
    <arm_group_label>3 = Control Product normal dose</arm_group_label>
    <arm_group_label>4 = Control Product high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects after receiving a full description of the study, provide written informed&#xD;
             consent to take part in the study.&#xD;
&#xD;
          -  Free-living subject, as evaluated during the clinical examination.&#xD;
&#xD;
          -  Male/female subjects aged between 18 to 55 years (bounds included).&#xD;
&#xD;
          -  Subjects with a body mass index (BMI) between 18.5 ≤ BMI &lt; 30kg/m².&#xD;
&#xD;
          -  Healthy subjects (as determined by a medical examination)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any allergy (food, respiratory…).&#xD;
&#xD;
          -  Subjects that have had any surgery or intervention requiring general anaesthesia in&#xD;
             the last 4 weeks.&#xD;
&#xD;
          -  Subjects with a history of chronic metabolic or gastrointestinal disease with the&#xD;
             exception of appendectomy.&#xD;
&#xD;
          -  Subjects with chronic or iatrogenic immunodeficiency (e.g. Chemotherapy, HIV).&#xD;
&#xD;
          -  Subjects presenting a severe evolutive or chronic pathology (e.g. cancer,tuberculosis,&#xD;
             Crohn's disease, cirrhosis, multiple sclerosis, Type I diabetes…).&#xD;
&#xD;
          -  Subject with eating disorders.&#xD;
&#xD;
          -  Subjects with cardiac, respiratory (including asthma) or renal insufficiency,&#xD;
             cardiomyopathy, valvulopathy and medical history of rheumatic fever.&#xD;
&#xD;
          -  Subjects with special medicated diet (for obesity, anorexia, metabolic pathology…).&#xD;
&#xD;
          -  For female subjects: pregnancy, breast-feeding or not willing to use/not using an&#xD;
             acceptable method of contraception&#xD;
&#xD;
          -  Subject, in the Investigator's opinion, should not be randomised.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harrison Clinical Research Clinical Unit, Hilblestrasse 54</name>
      <address>
        <city>München</city>
        <zip>D-80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy adults</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

